Lunai Bioworks Launches LouLou-Funded AI and Organoid Collaboration for Parkinson’s, Rare Epilepsy
LNAI•BioSymetrics, Lunai Bioworks’ subsidiary, and BrainStorm Therapeutics secured a LouLou Foundation grant to combine AI-driven target discovery, zebrafish validation and human midbrain organoid modeling for Parkinson’s disease and rare genetic epilepsies. The program aims to generate translational CNS assets and progression-linked biomarkers for pharmaceutical partnering and licensing.
1. Strategic Collaboration and Funding
Lunai Bioworks’ BioSymetrics subsidiary and BrainStorm Therapeutics entered a Letter of Intent supported by a LouLou Foundation grant to discover and validate novel neurology targets. The collaboration formalises joint efforts on Parkinson’s disease and rare genetic epilepsies under a translational research framework.
2. Integrated Discovery Platform
The program combines BioSymetrics’ AI-driven target identification with in vivo zebrafish validation and BrainStorm’s human midbrain organoid models. This integrated approach seeks to improve translational relevance and accelerate identification of high-confidence therapeutic targets.
3. Focus on Biomarker and Target Identification
Initial efforts leverage the Parkinson’s Progression Markers Initiative dataset alongside organoid analyses to pinpoint progression-linked biomarkers and actionable targets. A flagship initiative with collaborators at Brigham and Women’s Hospital zeroes in on rare genetic epilepsy mechanisms and therapeutic candidate generation.
4. Development Pipeline and Partnering Strategy
The collaboration aims to advance validated targets into development-ready assets for pharmaceutical partnering, licensing, and asset-based financings. A structured framework outlines target prioritisation, rapid validation and engagement strategies to create multiple value-generating neurology programs.
